RMTIHIGH SIGNALOPERATIONAL10-K

RMTI closed its South Carolina manufacturing facility in Q3 2025 and ended its contract manufacturing agreement, consolidating operations while experiencing dramatic profitability deterioration despite quadrupling revenue.

The operational consolidation suggests management is actively streamlining the business structure, but the massive swing from operating profit to significant losses indicates serious efficiency or cost control issues. The facility closure and contract termination may create short-term disruption but could position the company for improved margins if integration is successful.

Comparing 2026-03-26 vs 2025-03-20View on EDGAR →
FINANCIAL ANALYSIS

Revenue surged 292% to $57.3M, likely driven by the Evoqua asset acquisition integration, but gross profit declined 33% and the company swung from $608K operating profit to a $4.7M operating loss, indicating severe margin compression. Operating cash flow turned negative at -$659K from +$4.2M positive, while the balance sheet showed mixed signals with reduced liabilities (-24%) and increased equity (+14%) but declining cash reserves (-32%). The dramatic profitability deterioration despite massive revenue growth suggests integration challenges and operational inefficiencies that management must address urgently.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-1007.1%
-$480K-$5.3M

Net income declined 1007.1% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-871.5%
$608K-$4.7M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Revenue
P&L
+291.7%
$14.6M$57.3M

Strong top-line growth of 291.7% — accelerating demand or successful expansion into new markets.

Operating Cash Flow
Cash Flow
-115.7%
$4.2M-$659K

Operating cash flow fell 115.7% — earnings quality concerns; investigate working capital changes and non-cash items.

Inventory
Balance Sheet
-40.7%
$5.8M$3.4M

Inventory drawn down 40.7% — strong sell-through or deliberate destocking; watch for supply constraints.

Gross Profit
P&L
-33.1%
$17.5M$11.7M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Current Liabilities
Balance Sheet
-32%
$14.1M$9.6M

Current liabilities reduced — improved short-term financial position and working capital health.

Cash & Equivalents
Balance Sheet
-31.6%
$15.7M$10.7M

Cash declined 31.6% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Liabilities
Balance Sheet
-24.3%
$26.6M$20.2M

Liabilities reduced 24.3% — deleveraging improves balance sheet strength and financial flexibility.

Stockholders Equity
Balance Sheet
+13.5%
$32.6M$37.0M

Equity base grew 13.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.

LANGUAGE CHANGES
NEW — 2026-03-26
PRIOR — 2025-03-20
ADDED
Our forward looking statements also include, without limitation, statements about our liquidity and capital resources; our ability to continue as a going concern; our ability to successfully integrate acquisitions; our ability to raise additional capital; our ability to successfully implement certain cost containment and cost-cutting measures; our ability to achieve and maintain profitability; our ability to successfully execute on our business strategy; and statements regarding our anticipated future financial condition, operating results, cash flows and business plans.
CitraPure , Dri-Sate , RenalPure , and SteriLyte are registered trademarks of Rockwell Medical.
Rockwell manufactures hemodialysis concentrates under current Good Manufacturing Practices ("cGMP") regulations at its two facilities in Michigan and Texas and manufactures dry acid concentrate mixers at its facility in Iowa.
The Company previously operated a manufacturing and warehouse facility in South Carolina, but the Company concluded manufacturing at that facility in the third quarter of 2025 as part of its ongoing efforts to streamline operations and improve efficiency.
SIGNIFICANT 2025 HIGHLIGHTS Rockwell Medical's key developments from 2025 include: In February 2025, we added a single-use bicarbonate cartridge to our hemodialysis concentrates product portfolio that is 510(k) approved by the FDA and comes in two sizes, 720 grams and 900 grams.
+7 more — sign up free →
REMOVED
CENTRISOL , CitraPure , Dri-Sate , RenalPure , RENASOL , SteriLyte , and Triferic are registered trademarks of Rockwell Medical.
Rockwell manufactures hemodialysis concentrates under current Good Manufacturing Practices ("cGMP") regulations at its three facilities in Michigan, South Carolina, and Texas and manufactures dry acid concentrate mixers at its facility in Iowa.
Additionally, through its asset acquisition of customer relationships, equipment and inventory related to the manufacturing and sale of hemodialysis concentrates products from Evoqua Water Technologies in July 2023, the Company manufactured hemodialysis concentrates under a contract manufacturing agreement ("CMA") with a third-party contract manufacturing organization ("CMO") in Minnesota until the CMA expired on December 31, 2024.
Since the CMA's expiration, the Company only manufactures Rockwell Medical hemodialysis concentrates through its own facilities.
Prior to the expiration of the CMA, the Company transitioned customer relationships acquired through the Purchase Agreement (as defined below) over to Rockwell Medical's hemodialysis concentrates products.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
HOFTHIGHHOFT completed a major divestiture of its Pulaski and Samuel Lawrence furniture ...
2026-04-17
CTRNHIGHCTRN underwent a dramatic operational turnaround with a complete repositioning f...
2026-04-15
ORBSHIGHORBS has undergone a complete business transformation from packaging and e-comme...
2026-04-15
BRFHHIGHBRFH completed a transformative acquisition of Arps Dairy in October 2025, drama...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →